Eplerenone reduces arterial thrombosis in diabetic rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 4, 2015, Pages 1085-1094

  Zakrzeska, Agnieszka ^a   Gromotowicz Popawska, Anna ^a   Szemraj, Janusz ^b   Szoka, Piotr ^a   Kisiel, Wioleta ^a   Purta, Tomasz ^a   Kasacka, Irena ^a   Chabielska, Ewa ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Medical University of ódz   (Poland)

Author keywords

Aldosterone; Arterial thrombosis; Diabetes; Eplerenone; Rats

Indexed keywords

EPLERENONE; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; INTERLEUKIN DERIVATIVE; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY MEDIA; ARTERY OCCLUSION; ARTERY WALL; ARTICLE; CAROTID ARTERY; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; ERYTHROCYTE COUNT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HYPERTROPHY; INCIDENCE; LEUKOCYTE COUNT; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; THROMBOCYTE COUNT; THROMBUS; TIME; WISTAR RAT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BLOOD FLOW; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HEMOSTASIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; THROMBOSIS; VASCULAR PATENCY;

ANIMALS; CAROTID ARTERIES; DIABETES MELLITUS, EXPERIMENTAL; HEMOSTASIS; INTERLEUKINS; MALE; RATS, WISTAR; REGIONAL BLOOD FLOW; SPIRONOLACTONE; THROMBOSIS; VASCULAR PATENCY;

EID: 84952904451     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313515037     Document Type: Article

References (57)

1. Struthers AD,. Aldosterone: Cardiovascular assault. Am Heart J 2002; 144: S2-S7.
2. Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J 2012; 33: 191-202.
3. Sato A, Funder JW,. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996; 137: 4145-4153.
4. Ducros E, Berthaut A, Mirshahi SS, et al. Aldosterone modifies hemostasis via upregulation of the protein-C receptor in human vascular endothelium. Biochem Biophys Res Commun 2008; 373: 192-196.
5. Stankiewicz A, Gromotowicz A, Szemraj J, et al. Acute aldosterone infusion enhances thrombosis development in normotensive rats. Thromb Haemost 2007; 98: 697-699.
6. Gromotowicz A, Szemraj J, Stankiewicz A, et al. Study of the mechanisms of aldosterone prothrombotic effect in rats. J Renin Angiotensin Aldosterone Syst 2011; 12: 430-439.
7. Pitt B, Remme W, Zannad F, et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
8. O'Keefe JH, Abuissa H, Pitt B,. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: Results from EPHESUS. Diabetes Obes Metab 2008; 10: 492-497.
9. Schafer A, Vogt C, Fraccarollo D, et al. Eplerenone improves vascular function and reduces platelet activation in diabetic rats. J Physiol Pharmacol 2010; 61: 45-52.
10. Giles AR,. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-1084.
11. Guarini S,. A highly reproducible model of arterial thrombosis in rats. J Pharmacol Toxicol Methods 1996; 35: 101-105.
12. Kaminska M, Mogielnicki A, Stankiewicz A, et al. Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats. J Physiol Pharmacol 2005; 56: 571-585.
13. Schumacher WA, Bostwick JS, Ogletree ML, et al. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats. J Pharmacol Exp Ther 2007; 322: 369-377.
14. Carr ME,. Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 2001; 15: 44-54.
15. Jax TW, Peters AJ, Plehn G, et al. Relevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2. Cardiovasc Diabetol 2009; 8: 24.
16. Rerup CC,. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 1970; 22: 485-518.
17. 2A receptors in promoting thrombosis in diabetes. J Pharmacol Sci 2012; 119: 243-250.
18. Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-977.
19. Emekli-Alturfan E, Kasikci E, Yarat A,. Tissue factor activities of streptozotocin induced diabetic rat tissues and the effect of peanut consumption. Diabetes Metab Res Rev 2007; 23: 653-658.
20. Breitenstein A, Tanner FC, Luscher TF,. Tissue factor and cardiovascular disease: Quo vadis? Circ J 2010; 74: 3-12.
21. Dai H, Yu Z, Fan X, et al. Dysfunction of annexin A2 contributes to hyperglycaemia-induced loss of human endothelial cell surface fibrinolytic activity. Thromb Haemost 2013; 109: 1070-1078.
22. Pandolfi A, Giaccari A, Cilli C, et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol 2001; 38: 71-76.
23. Hagiwara H, Kaizu K, Uriu K, et al. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models. Thromb Res 2003; 111: 301-309.
24. Yuan J, Jia R, Bao Y,. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 2007; 8: 118-126.
25. Dunn EJ, Ariens RA, Grant PJ,. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198-1206.
26. Marchi-Cappelletti R, Suarez-Nieto N,. Preliminary study of the fibrin structure in hypertensive, dyslipidemic and type 2 diabetic patients. Invest Clin 2010; 51: 315-324.
27. Pieters M, Covic N, Loots du T, et al. The effect of glycaemic control on fibrin network structure of type 2 diabetes subject. Thromb Haemost 2006; 96: 623-629.
28. Yamashita A, Furukoji E, Marutsuka K, et al. Increased vascular wall thrombogenicity combined with reduced blood flow promotes occlusive thrombus formation in rabbit femoral artery. Arterioscler Thromb Vasc Biol 2004; 24: 2420-2424.
29. Chen H, Brahmbhatt S, Gupta A, et al. Duration of streptozotocin-induced diabetes differentially affects p38-mitogen-activated protein kinase (MAPK) phosphorylation in renal and vascular dysfunction. Cardiovasc Diabetol 2005; 4: 3.
30. Vranes D, Cooper ME, Dilley RJ,. Cellular mechanisms of diabetic vascular hypertrophy. Microvascular Research 1999; 57: 8-18.
31. Gilbert RE, Rumble JR, Cao Z, et al. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res 2000; 86: 158-165.
32. Sotnikova R, Skalska S, Okruhlicova L, et al. Changes in the function and ultrastruture of vessels in the rat model of multiple low dose streptozotocin-induced diabetes. Gen Physiol Biophys 2006; 25: 289-302.
33. Winocour PD,. Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41: 26-31.
34. Kawasaki T, Kawamura S, Katoh S, et al. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator. Japan J Pharmacol 1993; 63: 135-142.
35. Wojewódzka-Zelezniakowicz M, Chabielska E, Mogielnicki A, et al. Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats. J Physiol Pharmacol 2006; 57: 231-245.
36. Szemraj J, Zakrzeska A, Brown G, et al. New derivative of staphylokinase SAK-RGD-K2-Hirul exerts thrombolytic effects in the arterial thrombosis model in rats. Pharmacol Rep 2011; 63: 1169-1179.
37. Kalaska B, Sokolowska E, Kaminski K, et al. Cationic derivative of dextran reverses anticoagulant activity of unfractioned heparyn in animal models of arterial and venous thrombosis. Eur J Pharmacol 2012; 686: 81-89.
38. Kramkowski K, Leszczynska A, Mogielnicki A, et al. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules. Arterioscler Thromb Vasc Biol 2012; 32: 2149-2157.
39. Chabielska E, Bycul U, Zakrzeska A, et al. Eplerenone, a new selective mineralocorticoid receptor antagonist, inhibits platelet adhesion and attenuates endothelial damage in arterial thrombosis model in diabetic rats. Thromb Res 2012; 130: S136-S137.
40. Fareed J, Hoppensteadt D, Iqbal O, et al. Practical issues in the development of argatroban: A perspective. Pathophysiol Haemost Thromb 2002; 32: S56-S65.
41. Satoh M, Ishikawa Y, Minami Y, et al. Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure. Heart 2006; 92: 979-980.
42. Tentolouris C, Tousoulis D, Antoniades C, et al. Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int J Cardiol 2004; 94: 301-305.
43. Levi M, Biemond BJ, van Zonneveld AJ, et al. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312.
44. Ahn JH, Hong HCH, Cho MJ, et al. Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats. Diabetes Metab J 2012; 36: 128-135.
45. Longstaff C, Thelwell C, Williams SC, et al. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: Kinetic and microscopic studies. Blood 2011; 117: 661-668.
46. Collet JP, Montalescot G, Lesty C, et al. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 2002; 90: 428-434.
47. Nagata K, Obata K, Xu J, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-664.
48. Brown NJ,. Aldosterone and vascular inflammation. Hypertension 2008; 51: 161-167.
49. Takai S, Jin D, Muramatsu M, et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005; 46: 1135-1139.
50. Suzuki J, Iwai M, Mogi M, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 917-921.
51. De Rita O, Hackam DG, Spence JD,. Effects of aldosterone on human atherosclerosis: Plasma aldosterone and progression of carotid plaque. Can J Cardiol 2012; 28: 706-711.
52. Mutch NJ, Thomas L, Moore NR, et al. TAFIa, PAI-I and alpha-antiplasmin: Complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007; 5: 812-817.
53. Koh PJ, Koitka A, Cooper ME, et al. Eplerenone does not attenuate diabetes-associated atherosclerosis. J Hypertens 2009; 27: 1431-1438.
54. Tada Y, Kitazato KT, Tamura T, et al. Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats. Hypertension 2009; 54: 552-557.
55. Rickard AJ, Funder JW, Morgan J, et al. Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration? Endocrinology 2007; 148: 4829-4835.
56. Bender SB, McGraw AP, Jaffe IZ, et al. Mineralocorticoid receptor-mediated vascular insulin resistance: An early contributor to diabetes-related vascular disease? Diabetes 2013; 62: 313-319.
57. Davidson MH,. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: Therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. Am J Cardiol 2012; 110: 43B-49B.